Brand Institute yalengeza mgwirizano wake wopambana ndi Global Blood Therapeutics (GBT) potchula mankhwala ovomerezeka a EMA, OXBRYTA, omwe amawonetsedwa pochiza hemolytic anemia chifukwa cha matenda a sickle cell (SCD) mwa odwala akulu ndi ana azaka 12 ndi kupitilira apo. monotherapy kapena kuphatikiza hydroxycarbamide (hydroxyurea). Izi zikutsatira kuvomereza kwa FDA ndi Health Canada kwa mankhwalawa mu 2019.
"Bungwe lonse la Brand Institute ndi Drug Safety Institute Team likuyamikira Global Blood Therapeutics pa kuvomereza kwa FDA kwa OXBRYTA," adatero Wapampando ndi CEO wa Brand Institute, James L. Dettore. "Thandizo losinthali lingathe kusintha kwambiri anthu aku Europe omwe ali ndi matendawa."
OXBRYTA ndi mankhwala oyamba omwe amavomerezedwa ku Europe omwe amaletsa mwachindunji hemoglobin ya sickle hemoglobin (HbS) polymerization, mamolekyulu a kudwala ndi kuwononga maselo ofiira a magazi mu SCD. OXBRYTA imagwira ntchito mwa kukulitsa kugwirizana kwa hemoglobin ndi okosijeni. Popeza kuti hemoglobini yokhala ndi okosijeni sipanga polymeri, OXBRYTA imalepheretsa kupangika kwa chikwakwa cha hemoglobini ndipo zotsatira zake zimadwala komanso kuwononga maselo ofiira a magazi.
"Tikukhulupirira kuti dzina lachidziwitso la OXBRYTA ndiloyenera kwambiri pazogulitsa," adatero Dettore. "Kuphatikiza pa mawu akuti 'oxygen' omwe amagwirizana nawo, kutengera momwe chinthucho chimagwirira ntchito, dzinali lili ndi zambiri zomwe timatsatira tikamapanga dzina latsopano lamankhwala."
ZOMWE MUNGACHITE PA NKHANIYI:
- Brand Institute announced its successful partnership with Global Blood Therapeutics (GBT) in naming their EMA-approved therapy, OXBRYTA, indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide (hydroxyurea).
- OXBRYTA is the first medicine approved in Europe that directly inhibits sickle hemoglobin (HbS) polymerization, the molecular basis of sickling and destruction of red blood cells in SCD.
- Since oxygenated sickle hemoglobin does not polymerize, OXBRYTA inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells.
